Neurizon inks $1.5M loan against R&D Tax Rebate
Neurizon Therapeutics (ASX:NUZ) retreated in intra-day trade on Wednesday after inking a non-dilutive loan agreement for $1.5 million to fund its current and future operations seeking to treat Huntington’s with its flagship drug NUZ-001.The funds in question are secured against it...
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
MFE | Ann: Change of ASX Code | 23/12/15 | 0 | 1.0K | |||
|
|||||||
MFE | Ann: Appendix 3X - Initial Director's Interest Notice | 17/12/15 | 0 | 697 | |||
|
|||||||
MFE | Ann: Appointment of Director | 17/12/15 | 0 | 721 | |||
|
|||||||
MFE | royals future | 16/12/15 | 14 | 9.5K | |||
|
|||||||
MFE | Ann: Change of Company Name & ASX Code | 14/12/15 | 0 | 849 | |||
|
|||||||
MFE | Ann: Appendix 3Y - Change of Director's Interest Notice x 3 | 12:35 | 0 | 599 | |||
|
|||||||
MFE | Ann: Expiry of Directors Options | 12:03 | 0 | 556 | |||
|
|||||||
MFE | Ann: Appendix 3B - New Option Issue | 11:52 | 0 | 665 | |||
|
See All Discussions